Biodesix (NASDAQ:BDSX) Director Purchases 100,000 Shares of Company Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 100,000 shares of the stock in a transaction on Tuesday, November 10th. The stock was bought at an average price of $10.02 per share, with a total value of $1,002,000.00. Following the completion of the acquisition, the director directly owned 655,810 shares of the company’s stock, valued at $6,571,216.20. This trade represents a 17.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Biodesix Stock Up 1.4%

Shares of Biodesix stock traded up $0.14 during trading on Thursday, hitting $10.26. The company’s stock had a trading volume of 81,644 shares, compared to its average volume of 488,181. Biodesix, Inc. has a 52 week low of $5.26 and a 52 week high of $31.97. The company has a market capitalization of $113.81 million, a PE ratio of -3.73 and a beta of 0.65. The company has a fifty day simple moving average of $24.57 and a two-hundred day simple moving average of $18.88. The company has a debt-to-equity ratio of 5.43, a quick ratio of 2.85 and a current ratio of 2.96.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.75) EPS for the quarter, hitting analysts’ consensus estimates of ($0.75). Biodesix had a negative return on equity of 442.34% and a negative net margin of 25.74%. The firm had revenue of $24.04 million for the quarter, compared to analysts’ expectations of $27.48 million. Equities research analysts predict that Biodesix, Inc. will post -2.95 earnings per share for the current year.

Top Biodesix Stories

These are some of the BDSX stories that stood out recently:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $34 price target despite lowering its forecasts, providing a potentially supportive analyst view. HC Wainwright Has Lowered Expectations for Biodesix Stock Price
• Negative Sentiment: HC Wainwright cut estimates across 2026 and 2027, including FY2026 EPS to a loss of $3.13 from $2.72 and FY2027 EPS to a loss of $2.18 from $1.57. The sizable revisions point to expectations of deeper losses and could weigh on investor sentiment.
• Negative Sentiment: Johnson Fistel launched an investigation into whether Biodesix or its officers made misleading statements or failed to disclose material information, following the stock’s sharp decline on Nov. 6. The inquiry is not a finding of wrongdoing, but it adds legal and reputational uncertainty. Johnson Fistel Announces Biodesix Investor Investigation

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. HC Wainwright lowered their price target on Biodesix from $38.00 to $34.00 and set a “buy” rating for the company in a research report on Monday. TD Cowen reissued a “buy” rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Lake Street Capital reduced their price objective on shares of Biodesix from $40.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, November 6th. Finally, Canaccord Genuity Group raised their price objective on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BDSX. Allworth Financial LP purchased a new stake in shares of Biodesix during the second quarter valued at $112,000. HighTower Advisors LLC bought a new stake in Biodesix in the 3rd quarter worth about $228,000. Walleye Capital LLC purchased a new position in Biodesix in the 1st quarter worth about $157,000. Renaissance Technologies LLC purchased a new position in Biodesix in the 1st quarter worth about $173,000. Finally, Cetera Investment Advisers raised its position in Biodesix by 20.0% in the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock worth $174,000 after buying an additional 2,000 shares during the last quarter. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.